CN103571849B - Gene, detection method and kit used for detecting depressive disorder - Google Patents
Gene, detection method and kit used for detecting depressive disorder Download PDFInfo
- Publication number
- CN103571849B CN103571849B CN201310339394.9A CN201310339394A CN103571849B CN 103571849 B CN103571849 B CN 103571849B CN 201310339394 A CN201310339394 A CN 201310339394A CN 103571849 B CN103571849 B CN 103571849B
- Authority
- CN
- China
- Prior art keywords
- gene
- atp1a1
- normal
- patient
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a target gene and a detection kit used for detecting depressive disorder. The target gene used for detecting the depressive disorder is ATP1A1, and nucleotide sequences of a real-time fluorescence quantification PCR (polymerase chain reaction) primer for detecting the gene are shown as SEQ ID NO.2-3. The invention also provides the detection kit used for quantitative detection on ATP1A1. Effective guidance is provided for clinic detection of the depressive disorder by application of the ATP1A1 in preparation of medicines for diagnosing, treating and preventing the depressive disorder.
Description
Technical field
The present invention relates to biology field, particularly relating to the target gene ATP1A1 for detecting dysthymia disorders, the invention still further relates to the method and test kit that detect ATP1A1 gene.
Background technology
Dysthymia disorders be a kind of common take mood disorder as the mental disorder of main body performance, its concrete cause of disease is still not clear, low for main clinical characteristics with remarkable and lasting mental state, and the low environment of getting along with it of mental state is unbecoming, suicidal thought and behavior can be there is in severe patient.Current dysthymia disorders has become the fourth-largest disease in the world, and expecting the year two thousand twenty may be only second to the second largest illness of the cardiopathic mankind by becoming, and dysthymia disorders will become the primary killers of the 21 century mankind.
Current Diagnosis of Depression is still confined to be diagnosed as master with clinical symptom.Because persistence psychological disorders at least occurs two weeks, severe conditions even at least continues 2 years ability and confirms, current diagnosis lacks fast, sensitive index, be difficult to confirm whether patient suffers from this disease or fallen ill at short notice, more do not have measure to carry out early prevention, avoid the generation of tragedy.Exploitation accurately and objectively dysthymia disorders laboratory diagnosis and method for estimating curative effect plays great pushing effect by the preventing and controlling of China's dysthymia disorders.
In view of familial and the brain environment metabolic disturbance of patients with depression known at present, the detection for the expression level of the special genes involved of individual patient dysthymia disorders can provide reliable laboratory diagnosis foundation for the assessment of the early diagnosis of dysthymia disorders and the state of an illness.Simultaneously carry out periodic monitoring for the gene of abnormal expression to can be antidepressant agents Treatment and Prognosis clear and definite guidance and evaluation are provided.
Summary of the invention
The object of the present invention is to provide the specific target gene for detecting dysthymia disorders, the present invention also aims to provide the method detecting this target gene.
For achieving the above object, the present invention is by gathering a large amount of normal people and clinically clarifying a diagnosis as the blood samples of patients of dysthymia disorders, carry out molecular biology genetic analysis, use fluorescence quantifying PCR method, according to typical curve, calculate the relative expression quantity of gene in Different Individual sample, the homologous genes expression amount of the gene of patients with depression and normal people is carried out statistics comparative analysis, find out the gene with notable statistics difference, be the special genes involved of dysthymia disorders.The human genomic sequence comparison reported with ncbi database, finds that database serial number is that the expression amount of ATP1A1 gene in patients with depression body of 476 is lower than normal people (P < 0.05).
The invention provides a kind of target gene for detecting dysthymia disorders, it is ATP1A1, and it has the sequence shown in SEQ ID NO.1.In addition, it will be appreciated by those skilled in the art that the specific fragment of this sequence also can as the target gene detecting dysthymia disorders.
In an embodiment of the invention, the specific primer sequence for the ATP1A1 gene-specific fragment that increases is:
ATP1A1-FP:5’-GGTCCCAACGCCCTCACTC-3’，
ATP1A1-RP:5’-ACCACACCCAGGTACAGATTATCG-3’。
The invention provides a kind of test kit for detecting dysthymia disorders, containing above-mentioned Auele Specific Primer.
The primer sequence that detection kit of the present invention contains is:
ATP1A1-FP:5’-GGTCCCAACGCCCTCACTC-3’，
ATP1A1-RP:5’-ACCACACCCAGGTACAGATTATCG-3’。
Further, detection kit provided by the invention, it also comprises: fluorescent quantitation reaction solution, reference gene.
Preferably, described reference gene is β-actin.
The invention provides above-mentioned primer and prepare the application in Diagnosis of Depression test kit.
Present invention also offers above-mentioned primer and prepare the application in Diagnosis of Depression reagent.
Above-mentioned detection kit, its real-time fluorescence quantitative PCR reacts 20 μ l reaction systems and is: template 2 μ l, primer ATP1A1-FP and ATP1A1-RP each 10mmol0.5 μ l, quick SYBR-Green Master Mix10 μ l, deionized water 7 μ l.
The working conditions of above-mentioned diagnostic kit is denaturation 95 DEG C of 20s; 95 DEG C of 3s, 60 DEG C of 30s, totally 40 circulations.
The invention provides ATP1A1 gene and detect the application in dysthymia disorders.
The invention provides ATP1A1 gene and prepare the application in Diagnosis of Depression reagent.
The invention provides the application of ATP1A1 gene in preparation dysthymia disorders detection kit.
The method of a kind of detection by quantitative ATP1A1 gene of the present invention, extract sample total serum IgE, reverse transcription is after cDNA, utilizes above-mentioned primer to carry out real-time fluorescence quantitative PCR, according to amplification curve result of determination.
Preferably, described sample is blood.
The reaction system of described real-time fluorescence quantitative PCR, when for 20 μ l reaction system, is preferably configured to: template 2 μ l, 10mmol upstream primer 0.5 μ l, 10mmol downstream primer 0.5 μ l, quick SYBR-Green Master Mix10 μ l, deionized water 7 μ l.
The response procedures of real-time fluorescence quantitative PCR of the present invention is: 95 DEG C of denaturation 20s; 95 DEG C of sex change 3s, 60 DEG C of annealing extend 30s, 40 circulations.
Solubility curve analysis condition: 95 DEG C of 15s, 60 DEG C of 1min, 95 DEG C of 15s, 60 DEG C of 15s.
The present invention must set up NTC to contrast (without Template Controls) and POS contrast (positive control) at every turn when detecting sample, two kinds of contrasts play a decisive role for result interpretation:
Effective amplification: NTC(-) and POS(+)
Invalid amplification: NTC(+) and POS(+) point out system to pollute
Invalid amplification: NTC(-) and POS(-) point out system mistake or reagent to lose efficacy.
Only have the sample detection result in the effective amplification situation of contrast just credible, otherwise test need repetition.
When two kinds of contrasts are for effectively increasing in the detection, sample results judging criterion is as follows:
The sample that Ct value is less than or equal to 38 is positive findings;
The sample that Ct value is greater than 40 is negative findings;
The sample of Ct value between 38-40 needs repetition, and revision test such as Ct value is still judged to be positive amplification lower than 40, is judged to be negative amplification more than 40.Drawing standard curve, calculates the relative expression quantity of gene:
The absolute copy number of the absolute copy number/reference gene of goal gene Relative copy number=goal gene.
The invention provides the ATP1A1 gene for detecting dysthymia disorders, and for the primer of this gene specific fragment that increases, have stronger specificity, the fluorescent quantitative PCR detection method utilizing this primer to carry out ATP1A1 gene simplifies the program that dysthymia disorders detects further.ATP1A1 gene provided by the invention can be used for the diagnosis of dysthymia disorders, treatment and prevention, for clinical detection dysthymia disorders provides effective guidance, also can be used for the preparation of antidepressant agents.The method of detection ATP1A1 gene of the present invention has detection accurately, and highly sensitive, high specificity, easy advantage accurately, has good Samples detection ability.
Accompanying drawing explanation
Fig. 1 is the quantitative fluorescent PCR typical curve of embodiment 2.
Fig. 2 is the fluorescent quantitative PCR solubility curve figure of embodiment 2.
Fig. 3 is the fluorescent quantitative PCR graphic representation of embodiment 2.
Embodiment
Following examples further illustrate content of the present invention, but should not be construed as limitation of the present invention.Without departing from the spirit and substance of the case in the present invention, the amendment do the inventive method, step or condition or replacement, all belong to scope of the present invention.
If do not specialize, the conventional means that technique means used in embodiment is well known to those skilled in the art.
The amplification of embodiment 1ATP1A1 gene specific fragment
After blood donor agrees to, with a large amount of normal people of anticoagulant tube collection with clarify a diagnosis clinically as the blood samples of patients of dysthymia disorders, heparin tube puts into ice chest immediately.Molecular biology method is analyzed all blood samples, the human genomic sequence comparison reported with ncbi database, use fluorescence quantifying PCR method, according to typical curve, calculate the relative expression quantity of same gene in Different Individual sample, the homologous genes expression amount of the gene of patients with depression and normal people is carried out statistics comparative analysis, what in patients with depression and normal people, expression amount level had an obvious significant difference thinks the special genes involved of dysthymia disorders, the expression amount of ATP1A1 gene in patients with depression body that to found that at ncbi database sequence number be 476 is starkly lower than normal people (P < 0.05), be the special genes involved of dysthymia disorders.
According to design of primers principle, use Primer Express Version3 software at ATP1A1 gene conserved sequence region design primer:
ATP1A1-FP:5’-GGTCCCAACGCCCTCACTC-3’，
ATP1A1-RP:5’-ACCACACCCAGGTACAGATTATCG-3’。
1, PureLink is used
tMrNA Mini Kit(invitrogen company, article No. 12183018A) test kit extracts total serum IgE in blood.
2, RNA concentration and quality evalution: the concentration and the OD260/280 that measure RNA with trace dna determinator, result is 1.88.
3, reverse transcription: with TAKARA test kit by following system reverse transcription RNA, reaction solution is formulated in and carries out on ice.
Table 1 reverse transcription PCR reaction response system
Reaction conditions: 37 DEG C of 15min, 85 DEG C of 5sec
With total serum IgE in whole blood for template, carry out RT-PCR with above-mentioned primer, amplified production size is 179bp, and after reclaiming purifying, PCR primer send biotech firm to check order, and belongs to ATP1A1 gene, is accredited as the specific fragment of ATP1A1 gene.
To reclaim the PCR primer of purifying conventionally, connect through carrier, transformed competence colibacillus cell, inserts in pGEM-T carrier by goal gene, builds the standard plasmid obtained containing ATP1A1 gene.
Embodiment 2 real-time fluorescence quantitative PCR detects the foundation of ATP1A1 genetic method
With the cDNA after total serum IgE reverse transcription in blood for template, the Auele Specific Primer related to embodiment 1 reacts primer for PCR, sets up the real-time fluorescence quantitative PCR reaction method detecting ATP1A1 gene.The present embodiment adopts Fast
green Master Mix fluorescent dye (applied biology company, article No. 4385612) real-time fluorescence quantitative PCR reacts 20 μ l reaction systems and is: template 2 μ l, 10mmol upstream primer 0.5 μ l, 10mmol downstream primer 0.5 μ l, quick SYBR-Green Master Mix10 μ l, deionized water 7 μ l.
Reaction conditions: denaturation 95 DEG C of 20s, (95 DEG C of 3s, 60 DEG C of 30s) 40 circulation.
Solubility curve is analyzed: 95 DEG C of 15s, 60 DEG C of 1min, 95 DEG C of 15s, 60 DEG C of 15s.
The standard quantitative formulating normal control gene and the special relevant ATP1A1 gene of dysthymia disorders expresses curve.With the lg value of normal concentration template for X-coordinate, with corresponding Ct value for ordinate zou, drawing standard curve, is shown in Fig. 1.By standard substance with 10 times for gradient carries out doubling dilution, be generally 5-6 gradient.Then with the standard substance after above-mentioned dilution for template carries out quantitatively the R of as can be seen from the figure this typical curve respectively
2be 0.996, the equation linear relationship that each goal gene obtains is good, R
2all be greater than 0.99, slope (slope) is all less than-3.Result shows: template logarithmic value and Ct value have extraordinary dependency.Solubility curve is shown in Fig. 2, and each goal gene all can obtain single product in each gradient reaction, and solubility curve is unimodal, and peak type is sharp keen, meets goal gene expansion.Real-time PCR blood sample from 35 patients with depression being carried out to ATP1A1 gene detects, and amplification curve diagram is shown in Fig. 3.
Embodiment 3 clinical application experiment 1
Adopt the venous blood of patients with depression, be collected in anticoagulant tube, put into ice chest at once, after 4 hours, start test.Use PureLink
tMrNA Mini Kit(invitrogen article No. 12183018A) test kit extracts RNA in blood, measuring RNA concentration is 32.03ng/ul, after adopting the quantitative fluorescent PCR of the embodiment of the present invention 5, as calculated, in the venous blood of strongly fragrant disease patient, Gene A TP1A1 is 33 copy numbers, lower than normal people's level (normal people is 9447 copy numbers)
Embodiment 4 clinical application experiment 2
Adopt 20 parts, the venous blood of patients with depression, 10 parts, normal people's venous blood, is collected in anticoagulant tube, puts into ice chest at once, starts test after 4 hours.Use PureLink
tMrNA Mini Kit(invitrogen article No. 12183018A) test kit extracts RNA in blood, after adopting the fluorescence quantifying PCR method of the embodiment of the present invention 2 to detect 30 parts of blood rnas, found that in the venous blood of 20 parts of patients with depression, the ATP1A1 of 17 parts of patients and the ratio of house-keeping gene are all less than mean value (mean value is the ATP1A1 of normal people and the ratio of house-keeping gene).Therefore, ATP1A1 gene can be used for diagnosing whether sample source is patients with depression or potential patients with depression.
Embodiment 5 clinical application experiment 3
Adopt patients with depression and each 35 parts of normal human connection blood, be collected in anticoagulant tube, put into ice chest at once, after 2 hours, start test.Use PureLink
tMrNA Mini Kit(invitrogen article No. 12183018A) test kit extracts RNA in blood, after adopting the embodiment of the present invention 2 fluorescence quantifying PCR method to detect 70 parts of blood rnas, found that the absolute copy number of ATP1A1 in the peripheral blood of patients with depression is lower than normal people, in table 2, (P<0.05), and the ratio of ATP1A1 and house-keeping gene β-actin be less than normal people (P<0.01) at patients with depression.Therefore, the ATP1A1 of patients with depression and normal people and the ratio of house-keeping gene β-actin have obvious difference.
Table 2
| Sample | ATP1A1 | ATP1A1/b-actin value | Sample | ATP1A1 | ATP1A1/b-actin value |
| Patient 1 | 1.27E-07 | 5.81E-03 | Normal 1 | 1.89E-06 | 2.03E-02 |
| Patient 2 | 4.58E-08 | 5.12E-03 | Normal 2 | 1.79E-06 | 1.19E-02 |
| Patient 3 | 5.61E-08 | 3.98E-03 | Normal 3 | 1.29E-06 | 1.36E-02 |
| Patient 4 | 4.66E-08 | 8.78E-04 | Normal 4 | 1.16E-06 | 1.76E-02 |
| Patient 5 | 1.19E-07 | 5.51E-03 | Normal 5 | 9.32E-08 | 2.65E-02 |
| Patient 6 | 6.63E-07 | 5.69E-03 | Normal 6 | 6.11E-07 | 1.03E-02 |
| Patient 7 | 4.67E-07 | 6.61E-03 | Normal 7 | 3.60E-07 | 2.05E-02 |
| Patient 8 | 6.21E-07 | 5.77E-03 | Normal 8 | 5.76E-07 | 1.17E-02 |
| Patient 9 | 7.84E-08 | 2.53E-03 | Normal 9 | 1.07E-07 | 1.11E-02 |
| Patient 10 | 1.10E-06 | 6.88E-03 | Normal 10 | 6.24E-07 | 1.24E-02 |
| Patient 11 | 1.93E-08 | 2.82E-03 | Normal 11 | 8.20E-07 | 2.87E-02 |
| Patient 12 | 2.92E-09 | 4.81E-04 | Normal 12 | 4.96E-07 | 2.26E-02 |
| Patient 13 | 3.78E-09 | 5.12E-04 | Normal 13 | 7.48E-07 | 2.10E-02 |
| Patient 14 | 1.76E-09 | 2.20E-04 | Normal 14 | 1.74E-07 | 1.53E-02 |
| Patient 15 | 4.99E-08 | 1.37E-02 | Normal 15 | 3.97E-07 | 1.79E-02 |
| Patient 16 | 2.84E-08 | 2.26E-03 | Normal 16 | 3.46E-09 | 7.24E-02 |
| Patient 17 | 5.87E-10 | 4.82E-05 | Normal 17 | 1.28E-07 | 5.78E-02 |
| Patient 18 | 1.96E-09 | 1.83E-04 | Normal 18 | 4.36E-09 | 1.85E-01 |
| Patient 19 | 8.70E-10 | 8.86E-05 | Normal 19 | 9.15E-08 | 3.53E-02 |
| Patient 20 | 1.22E-09 | 1.05E-04 | Normal 20 | 1.63E-08 | 5.52E-02 |
| Patient 21 | 1.48E-08 | 1.32E-03 | Normal 21 | 1.39E-07 | 1.46E-02 |
| Patient 22 | 1.27E-07 | 1.43E-02 | Normal 22 | 6.22E-08 | 2.78E-02 |
| Patient 23 | 3.73E-10 | 6.64E-05 | Normal 23 | 8.52E-08 | 3.25E-02 |
| Patient 24 | 1.89E-09 | 5.79E-03 | Normal 24 | 7.04E-08 | 2.47E-02 |
| Patient 25 | 2.90E-07 | 4.68E-03 | Normal 25 | 1.94E-07 | 2.06E-02 |
| Patient 26 | 7.55E-08 | 6.07E-03 | Normal 26 | 3.97E-07 | 1.78E-02 |
| Patient 27 | 2.55E-07 | 1.06E-02 | Normal 27 | 1.74E-07 | 1.53E-02 |
| Patient 28 | 1.02E-07 | 8.58E-03 | Normal 28 | 7.48E-07 | 2.10E-02 |
| Patient 29 | 1.82E-09 | 8.11E-05 | Normal 29 | 4.96E-07 | 2.26E-02 |
| Patient 30 | 1.80E-07 | 1.04E-02 | Normal 30 | 8.20E-07 | 2.87E-02 |
| Patient 31 | 3.31E-08 | 1.74E-03 | Normal 31 | 1.81E-07 | 2.11E-02 |
| Patient 32 | 5.13E-09 | 2.40E-04 | Normal 32 | 2.57E-08 | 5.88E-02 |
| Patient 33 | 1.08E-08 | 5.79E-04 | Normal 33 | 1.73E-08 | 8.36E-02 |
| Patient 34 | 4.88E-08 | 2.44E-03 | Normal 34 | 7.83E-08 | 5.09E-02 |
| Patient 35 | 1.27E-07 | 5.93E-03 | Normal 35 | 5.30E-08 | 3.71E-02 |
| Average | 1.35E-07 | 4.06E-03 | Average | 4.26E-07 | 3.27E-02 |
Embodiment 6 clinical application experiment 4
Take the blood of certain 100 Patients patient at random, be collected in anticoagulant tube, put into ice chest at once, after 2 hours, start test.By medical practitioner, Diagnosis of Depression is carried out to 100 people simultaneously.Use PureLink
tMrNA Mini Kit(invitrogen article No. 12183018A) test kit extracts RNA in blood, the embodiment of the present invention 2 fluorescence quantifying PCR method is adopted to carry out fluorescent quantitation test, calculate the absolute copy number of ATP1A1 and the ratio of ATP1A1 and house-keeping gene β-actin respectively, the results are shown in Table 3.Found that, in experimental result, the dysthymia disorders scale score of the sample that the ratio of ATP1A1 and house-keeping gene β-actin is low is high, the dysthymia disorders scale score that the ratio of ATP1A1 and house-keeping gene β-actin is high is low, therefore, the ratio of ATP1A1 and house-keeping gene β-actin can point out dysthymia disorders scale score.The efficacy evaluation of dysthymia disorders adopts Hamilton depressive scale (HAMD) Hamilton depressive scale operation instruction http://wenku.baidu.com/view/9b23e742e45c3b3567ec8b51.html.
Table 3
| The absolute copy number of ATP1A1 | ATP1A1/B-ACTIN | Depression scores | Anxiety scores | |
| 1 | 7.16E+02 | 3.00E-03 | 17 | 25 |
| 2 | 8.57E+03 | 4.14E-03 | 26 | 32 |
| 3 | 2.36E+04 | 7.34E-03 | 0 | 6 |
| 4 | 4.83E+05 | 6.46E-02 | 1 | 1 |
| 5 | 2.23E+05 | 4.35E-01 | 1.15 | 1 |
| 6 | 1.54E+05 | 3.37E-02 | 1 | 1 |
| 7 | 6.81E+04 | 1.55E-02 | 1 | 1 |
| 8 | 1.64E+03 | 1.47E-02 | 1.15 | 1 |
| 9 | 3.32E+02 | 1.31E-02 | 1 | 1 |
| 10 | 3.09E+03 | 2.44E-02 | 1 | 1 |
| 11 | 1.76E+03 | 3.43E-02 | 1.07 | 1 |
| 12 | 5.66E+04 | 2.04E-02 | 1 | 1 |
| 13 | 8.44E+04 | 8.60E-02 | 1.07 | 1.1 |
| 14 | 1.27E+05 | 1.64E-02 | 1.23 | 1.1 |
| 15 | 6.45E+05 | 2.10E-02 | 1.07 | 1 |
| 16 | 3.04E+05 | 3.10E-02 | 1.3 | 1.3 |
| 17 | 1.26E+05 | 3.06E-02 | 1.3 | 1 |
| 18 | 2.35E+05 | 3.04E-01 | 1 | 1 |
| 19 | 9.70E+04 | 1.49E-01 | 1.92 | 1.6 |
| 20 | 1.92E+04 | 2.49E-02 | 1 | 1 |
| 21 | 7.42E+04 | 2.32E-02 | 1 | 1 |
| 22 | 1.22E+05 | 5.68E-02 | 1 | 1 |
| 23 | 7.91E+04 | 3.76E-02 | ||
| 24 | 6.35E+04 | 1.37E-01 | 1 | 1 |
| 25 | 1.77E+05 | 1.46E-02 | 1.23 | 1 |
| 26 | 7.57E+04 | 1.64E-01 | 1 | 1.1 |
| 27 | 1.58E+04 | 3.18E-02 | 1 | 1 |
| 28 | 1.79E+04 | 2.07E-01 | 1.15 | 1 |
| 29 | 6.67E+04 | 2.26E-02 | 1 | 1 |
| 30 | 7.75E+04 | 2.50E-01 | 1.15 | 1 |
| 31 | 1.05E+05 | 1.99E-02 | 1 | 1 |
| 32 | 1.25E+05 | 2.04E-02 | 1.07 | 1 |
| 33 | 1.71E+05 | 2.78E-02 | 1 | 1 |
| 34 | 1.82E+05 | 1.13E-01 | 1 | 1 |
| 35 | 2.50E+04 | 1.54E-01 | 1 | 1 |
| 36 | 1.77E+05 | 2.42E-02 | ||
| 37 | 3.72E+05 | 1.74E-02 | 1.07 | 1 |
| 38 | 3.86E+04 | 1.32E-01 | 1 | 1 |
| 39 | 1.43E+04 | 4.89E-02 | 1 | 1 |
| 40 | 2.94E+04 | 4.74E-02 | 1 | 1.2 |
| 41 | 2.13E+04 | 4.99E-02 | 1 | 1 |
| 42 | 5.78E+03 | 1.52E-02 | 1.15 | 1.1 |
| 43 | 1.55E+03 | 2.55E-02 | 1 | 1.1 |
| 44 | 7.70E+02 | 1.67E-02 | 1.3 | 1.1 |
| 45 | 5.32E+03 | 1.67E-02 | 1 | |
| 46 | 3.55E+03 | 2.39E-02 | 1 | 1 |
| 47 | 2.13E+02 | 7.07E-02 | 1.07 | 1 |
| 48 | 6.90E+01 | 2.43E-02 | 1 | 1 |
| 49 | 1.04E+03 | 1.23E-02 | 1.07 | 1 |
| 50 | 9.64E+03 | 4.37E-02 | 1 | 1 |
| 51 | 1.69E+05 | 2.92E-02 | 1 | 1 |
| 52 | 2.54E+04 | 6.10E-02 | 1 | 1 |
| 53 | 8.54E+03 | 1.33E-01 | 1 | 1 |
| 54 | 1.64E+03 | 1.60E-02 | 1 | 1 |
| 55 | 6.63E+03 | 1.95E-02 | 1 | 1 |
| 56 | 5.17E+04 | 4.36E-02 | 1.53 | 1.4 |
| 57 | 2.23E+03 | 3.80E-02 | 1 | 1 |
| 58 | 1.41E+03 | 1.04E-02 | 1.23 | 1.2 |
| 59 | 3.23E+03 | 2.02E-02 | 1 | 1.1 |
| 60 | 3.64E+03 | 1.38E-02 | ||
| 61 | 1.22E+05 | 1.74E-02 | 1.61 | 1.8 |
| 62 | 4.50E+04 | 2.67E-02 | 1 | 1 |
| 63 | 1.37E+04 | 2.01E-02 | 1 | 1 |
| 64 | 1.32E+04 | 2.03E-02 | 1.15 | 1.1 |
| 65 | 9.24E+04 | 5.24E-02 | 1.3 | 1 |
| 66 | 2.53E+03 | 1.33E-02 | 1.23 | 1.1 |
| 67 | 2.38E+03 | 2.52E-02 | 1.15 | 1.3 |
| 68 | 2.91E+03 | 1.24E-02 | 1.07 | 1 |
| 69 | 7.80E+03 | 3.50E-02 | 1 | 1 |
| 70 | 4.89E+04 | 4.89E-02 | 1 | 1 |
| 71 | 2.81E+02 | 1.17E-02 | 1.23 | 1 |
| 72 | 4.12E+02 | 2.84E-02 | 1 | 1.1 |
| 73 | 3.17E+03 | 1.15E-02 | 1 | 1 |
| 74 | 2.05E+04 | 1.57E-02 | 1.07 | 1 |
| 75 | 3.40E+02 | 1.79E-02 | 1 | 1 |
| 76 | 1.39E+05 | 5.05E-02 | 1 | 1.3 |
| 77 | 2.59E+03 | 1.55E-02 | 1 | 1 |
| 78 | 2.02E+04 | 3.98E-02 | 1.69 | 1.2 |
| 79 | 4.02E+03 | 3.14E-02 | 1.07 | 1 |
| 80 | 4.84E+02 | 1.95E-02 | 1.07 | 1.1 |
| 81 | 2.25E+03 | 3.64E-02 | 1.15 | 1.1 |
| 82 | 4.99E+03 | 5.64E-02 | 1.15 | 1.1 |
| 83 | 2.07E+02 | 1.92E-02 | 1 | 1 |
| 84 | 6.90E+02 | 3.64E-02 | 1.25 | 1.1 |
| 85 | 5.88E+04 | 7.37E-02 | ||
| 86 | 6.47E+02 | 1.34E-02 | 1.3 | 1 |
| 87 | 1.27E+04 | 4.51E-01 | 1 | 1 |
| 88 | 1.07E+03 | 2.16E-02 | 1.07 | 1 |
| 89 | 8.67E+03 | 2.85E-02 | 1 | 1 |
| 90 | 2.15E+04 | 1.91E-02 | 1 | 1.1 |
| 91 | 5.84E+03 | 1.85E-02 | 1 | 1 |
| 92 | 7.09E+03 | 3.10E-02 | 1 | 1 |
| 93 | 5.86E+03 | 3.64E-02 | ||
| 94 | 1.15E+04 | 1.81E-02 | 1 | 1.1 |
| 95 | 5.93E+03 | 1.72E-02 | 1 | 1 |
| 96 | 6.17E+03 | 2.53E-02 | 1.07 | |
| 97 | 6.01E+03 | 4.45E-02 | 1 | 1 |
| 98 | 1.03E+04 | 1.59E-02 | 1 | 1 |
| 99 | 1.56E+04 | 1.01E-02 | 1 | 1 |
| 100 | 2.47E+06 | 1.47E-02 | 1.07 | 1 |
Claims (1)
1.ATP1A1 gene is preparing the application in Diagnosis of Depression reagent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310339394.9A CN103571849B (en) | 2012-08-06 | 2013-08-06 | Gene, detection method and kit used for detecting depressive disorder |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210277504 | 2012-08-06 | ||
| CN201210277504.9 | 2012-08-06 | ||
| CN2012102775049 | 2012-08-06 | ||
| CN201310339394.9A CN103571849B (en) | 2012-08-06 | 2013-08-06 | Gene, detection method and kit used for detecting depressive disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103571849A CN103571849A (en) | 2014-02-12 |
| CN103571849B true CN103571849B (en) | 2015-05-13 |
Family
ID=50044560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310339394.9A Active CN103571849B (en) | 2012-08-06 | 2013-08-06 | Gene, detection method and kit used for detecting depressive disorder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103571849B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107056888A (en) * | 2017-03-01 | 2017-08-18 | 中山大学肿瘤防治中心 | ATP1A1 target polypeptides and application |
| CN108531569B (en) * | 2017-03-03 | 2021-05-07 | 上海伯豪医学检验所有限公司 | Gene marker for screening obsessive-compulsive disorder, schizophrenia and depression and application thereof |
| CN107385101A (en) * | 2017-09-14 | 2017-11-24 | 西南医科大学附属医院 | A kind of kit and its application for detecting Clinical depression mood and depression |
| CN108148903A (en) * | 2018-02-13 | 2018-06-12 | 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) | Applications of the CCL3L3 in the diagnosis, treatment and prognosis of depression |
| CN108148905A (en) * | 2018-02-13 | 2018-06-12 | 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) | One section can be as the sequence of depression marker |
| CN111141863B (en) * | 2018-11-06 | 2021-08-10 | 中国科学院大连化学物理研究所 | Application of reagent of depression diagnosis marker in preparation of depression diagnosis kit |
| CN109825571A (en) * | 2019-03-04 | 2019-05-31 | 中国科学院昆明动物研究所 | Depression detects biomarker and its kit |
| CN113073137B (en) * | 2021-04-02 | 2022-09-30 | 武汉儿童医院 | Postpartum depression detection reagent, system and application |
| CN112980944B (en) * | 2021-04-26 | 2022-07-08 | 武汉儿童医院 | Major depression detection reagent, system and application |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101294220A (en) * | 2008-06-18 | 2008-10-29 | 山西医科大学 | Method for estimating major depression coming on susceptibility |
| CN101338337A (en) * | 2007-07-04 | 2009-01-07 | 北京华安佛医药研究中心有限公司 | Polymorphism site genotype estimation depression, use and process of medicine effect and kit |
| CN102099492A (en) * | 2008-05-15 | 2011-06-15 | 通用电气健康护理有限公司 | Biomarkers for depression |
| CN102146479A (en) * | 2011-04-15 | 2011-08-10 | 上海交通大学 | Primers and probes for detecting genes associated with schizophrenia, bipolar affective disorders and major depression and kits and preparation methods thereof |
| CN103146822A (en) * | 2013-02-26 | 2013-06-12 | 天津市安定医院 | PCR (Polymerase Chain Reaction) kit for detecting SNP (Single Nucleotide Polymorphism) relative to female depression |
-
2013
- 2013-08-06 CN CN201310339394.9A patent/CN103571849B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101338337A (en) * | 2007-07-04 | 2009-01-07 | 北京华安佛医药研究中心有限公司 | Polymorphism site genotype estimation depression, use and process of medicine effect and kit |
| CN102099492A (en) * | 2008-05-15 | 2011-06-15 | 通用电气健康护理有限公司 | Biomarkers for depression |
| CN101294220A (en) * | 2008-06-18 | 2008-10-29 | 山西医科大学 | Method for estimating major depression coming on susceptibility |
| CN102146479A (en) * | 2011-04-15 | 2011-08-10 | 上海交通大学 | Primers and probes for detecting genes associated with schizophrenia, bipolar affective disorders and major depression and kits and preparation methods thereof |
| CN103146822A (en) * | 2013-02-26 | 2013-06-12 | 天津市安定医院 | PCR (Polymerase Chain Reaction) kit for detecting SNP (Single Nucleotide Polymorphism) relative to female depression |
Non-Patent Citations (5)
| Title |
|---|
| 5-羟色胺及其受体与抑郁症;秦娟娟 等;《国际药学研究杂》;20121031;第39卷(第5期);409-415 * |
| AC004904;Sulston,J.E.等;《GENBANK》;20001108;1－70 * |
| AL136376;Matthews,N.;《GENBANK》;20041123;1-24 * |
| Na/K ATP酶活性及其ATP1A1基因多态性与2 型糖尿病周围神经病变的相关性;张雪冰 等;《中国糖尿病杂志》;20070430;第15卷(第4期);222-224 * |
| 抑郁症相关基因数据库的构建;王栋 等;《中国临床康复》;20050828;第9卷(第32期);30-31 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103571849A (en) | 2014-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103571849B (en) | Gene, detection method and kit used for detecting depressive disorder | |
| CN107849610B (en) | Method for diagnosing early Alzheimer's disease or mild cognitive impairment | |
| US20120322680A1 (en) | Use of mirnas as biomarkers in glioma diagnosis | |
| EP2280078B1 (en) | Marker for determination of breast cancer, test method, and test kit | |
| Qin et al. | Preliminary study of hsa-miR-626 change in the cerebrospinal fluid of Parkinson’s disease patients | |
| CN101613748A (en) | A kind of method that detects serum marker of pancreatic cancer | |
| KR20130029079A (en) | Marker consisting of plasma microrna and a new method for diagnosis of hepatocellular carcinoma | |
| WO2016117582A1 (en) | Marker for determining mental illness using mirna | |
| CN104480106A (en) | Serum/plasma micro-RNA marker for detecting patients with mild cognitive impairment and application thereof | |
| Elkhodiry et al. | miR-155 and functional proteins of CD8+ T cells as potential prognostic biomarkers for relapsing-remitting multiple sclerosis | |
| CN106676185A (en) | In-blood exosome micro ribonucleic acid (miRNA) spectrum and detection kit for predicting incidence of individual aneurysm | |
| CN114015767B (en) | Serum circRNA marker for identifying craniosynostosis and application thereof | |
| JP5748736B2 (en) | Marker for detecting myogenic disease and detection method using the same | |
| Ali et al. | The Ifng antisense RNA 1 (IFNG-AS1) and growth arrest-specific transcript 5 (GAS5) are novel diagnostic and prognostic markers involved in childhood ITP | |
| KR20140130648A (en) | SNP markers for abdominal obesity and use thereof | |
| Amin et al. | Liver specific serum micro RNA122as a prognostic marker in Egyptian patients with liver cirrhosis | |
| US10815527B2 (en) | Determination of platelet-miRNAs in alzheimer's disease | |
| Su-ying et al. | Increased expression of microRNA-155 in the serum of women with early-stage breast cancer | |
| US10487359B2 (en) | Method for diagnosing fibromyalgia using microRNAs | |
| WO2018219998A1 (en) | Mirnas as biomarkers for a systemic inflammatory response syndrome | |
| CN106544435A (en) | Needed for detection miR 206, reverse transcriptase primer is to the application in prediction test kit is prepared | |
| JP2015133919A (en) | biomarkers of amyotrophic lateral sclerosis | |
| AU2021105761A4 (en) | Use of microRNA markers microRNA-130a and microRNA-130b in diagnosis of Hepatic fibrosis | |
| CN108753955A (en) | The biomarker of coronary artery stenosis and application | |
| CN113817818B (en) | Tool for diagnosing allergic airway inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |